Market closedNon-fractional
ProQR Therapeutics/PRQR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ProQR Therapeutics
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
Ticker
PRQR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Leiden, Netherlands
Employees
-
Website
www.proqr.com
PRQR Metrics
BasicAdvanced
$150M
Market cap
-
P/E ratio
-$0.36
EPS
0.34
Beta
-
Dividend rate
Price and volume
Market cap
$150M
Beta
0.34
Financial strength
Current ratio
3.113
Quick ratio
3.076
Long term debt to equity
38.405
Total debt to equity
55.214
Interest coverage (TTM)
-50.80%
Management effectiveness
Return on assets (TTM)
-14.84%
Return on equity (TTM)
-56.75%
Valuation
Price to revenue (TTM)
12.06
Price to book
3.97
Price to tangible book (TTM)
3.97
Price to free cash flow (TTM)
-3.937
Growth
Revenue change (TTM)
176.00%
Earnings per share change (TTM)
-58.69%
3-year revenue growth
126.63%
3-year earnings per share growth
-27.31%
What the Analysts think about PRQR
Analyst Ratings
Majority rating from 7 analysts.
PRQR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€4.6M
-25.81%
Net income
-€7.6M
40.74%
Profit margin
-165.21%
89.70%
PRQR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-€0.10
-€0.07
-€0.07
-€0.09
-
Expected
-€0.11
-€0.09
€0.01
-€0.11
-€0.13
Surprise
-9.79%
-18.02%
-710.93%
-18.42%
-
PRQR News
AllArticlesVideos
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
Seeking Alpha·2 months ago
ProQR Announces First Quarter 2024 Operating and Financial Results
GlobeNewsWire·2 months ago
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ProQR Therapeutics stock?
ProQR Therapeutics (PRQR) has a market cap of $150M as of July 06, 2024.
What is the P/E ratio for ProQR Therapeutics stock?
The price to earnings (P/E) ratio for ProQR Therapeutics (PRQR) stock is 0 as of July 06, 2024.
Does ProQR Therapeutics stock pay dividends?
No, ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next ProQR Therapeutics dividend payment date?
ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders.
What is the beta indicator for ProQR Therapeutics?
ProQR Therapeutics (PRQR) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell ProQR Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.